John Koren

Research Scholar
John Koren
Lab Phone
646-888-2216

I am examining the mechanisms which allow some cancer-cell models to survive following Hsp90 inhibition.  These studies cover cancer biology, basic Hsp90 biochemistry, signal transduction, and pharmacology.

I am also studying the effects of a unique blood-brain barrier permeable Hsp90 inhibitor as a therapeutic option for neurodegenerative diseases.  These studies include neurobiology, animal behavior analysis, and basic neural-biochemistry.

CURRENT: https://www.researchgate.net/profile/John_Koren

University of Notre Dame | ND · Warren Family Research Center for Drug Discovery and Development

Publications

Selected Publications

Kishinevsky S, Wang T, Rodina A, Chung SY, Xu C, Philip J, Taldone T, Joshi S, Alpaugh ML, Bolaender A, Gutbier S, Sandhu D, Fattahi F, Zimmer B, Shah SK, Chang E, Inda C, Koren J 3rd, Saurat NG, Leist M, Gross SS, Seshan VE, Klein C, Tomishima MJ, Erdjument-Bromage H, Neubert TA, Henrickson RC, Chiosis G*, Studer L*. HSP90-incorporating chaperome networks as biosensor for disease-related pathways in patient-specific midbrain dopamine neurons. Nat Commun. 2018 Oct 19;9(1):4345. doi: 10.1038/s41467-018-06486-6.

Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H, Caldas-Lopes E, Alpaugh M, Corben A, Riolo M, Beattie B, Pressl C, Peter RI, Xu C, Trondl R, Patel HJ, Shimizu F, Bolaender A, Yang C, Panchal P, Farooq MF, Kishinevsky S, Modi S, Lin O, Chu F, Patil S, Erdjument-Bromage H, Zanzonico P, Hudis C, Studer L, Roboz GJ, Cesarman E, Cerchietti L, Levine R, Melnick A, Larson SM, Lewis JS, Guzman ML, Chiosis G. The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. 2016;538(7625):397-401. PMCID: PMC5283383. Altmetric 439. PubMed

Carmen A, Kishinevsky S, Koren J 3rd, Luo W, Chiosis G. Regulatory Chaperone Complexes in Neurodegenerative Diseases: A Perspective on Therapeutic Intervention, Current Alzheimer’s Research, Nov. 2013

Guzman ML; Lowery MA, Taldone T, Koren J, Gomes EDG, Chiosis G. Molecular Chaperones and How Addiction Matters in Cancer Therapy. Cell Death Signaling in Cancer Biology and Treatment p181-203. 2013 New York: Springer

Koren J 3rd, Miyata Y, Kiray J, O’Leary JC 3rd, Nguyen L, Guo J, Blair LJ, Li X, Jinwal UK, Cheng JQ, Gestwicki JE, Dickey CA. Rhodacyanine Derivative Selectively Targets Cancer Cells and Overcomes Tamoxifen Resistance. PLoS One Apr. 2012.

Koren J 3rd, Jinwal UK, Davey Z, Kiray J, Arulselvam K, Dickey CA. Bending Tau into Shape: The Emerging Role of Peptidyl-Prolyl Isomerase in Tauopathies. Molecular Neurobiology Aug. 2011.

Koren J 3rd, Jinwal UK, Jin Y, O’Leary J, Jones JR, Johnson AG, Blair LJ, Abisambra JF, Chang L, Miyata Y, Cheng AM, Guo J, Cheng JQ, Gestwicki JE, Dickey CA. Facilitating Akt clearance via manipulation of Hsp70 activity and levels. Journal of Biological Chemistry Jan. 2010.

Koren J, Jinwal UK, Lee D, Jones J, Shults C, Johnson A, Anderson LJ, Dickey CA. Review: Chaperone Signaling Complexes in Alzheimer’s Disease. Journal of Cellular and Molecular Medicine Apr. 2009.

Dickey CA, Koren J, Zhang YJ, Xu YF, Jinwal UK, Birnbaum MJ, Monks B, Sun M, Cheng JQ, Patterson C, Bailey RM, Dunmore J, Soresh S, Leon C, Morgan D, Petrucelli L. Akt and CHIP Co-regulate Tau Degradation Through Coordinated Interactions. Proceedings of the National Academy of Sciences U.S.A. Mar. 2008